SCHEMBL3341819

SCHEMBL3341819

COC(=O)CCCC(=O)C#C[Si](C)(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.56
GLA P06280 1/20 0.40
LMNA P02545 2/20 0.38
ALDH1A1 P00352 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CA12 O43570 2/20 0.33
CA14 Q9ULX7 2/20 0.33
KDM4E B2RXH2 1/20 0.33
RECQL P46063 1/20 0.33
OXER1 Q8TDS5 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA3 P07451 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
CA5A P35218 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA13 Q8N1Q1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25224556 0.96 TSHR (0.50) TSHRGLALMNAALDH1A1MEN1
SCHEMBL3342475 0.89 TSHR (0.52) TSHRGLALMNAALDH1A1MEN1
SCHEMBL3411217 0.81 LMNA (0.47) TSHRLMNAALDH1A1
SCHEMBL12199134 0.79 TSHR (0.62) TSHRGLALMNAALDH1A1MEN1
SCHEMBL13950322 0.77 TSHR (0.60) TSHRGLALMNAALDH1A1MEN1
SCHEMBL11347415 0.76 CES1 (0.42) TSHRALDH1A1MEN1KMT2ACA1
SCHEMBL12931198 0.76 TSHR (0.38) TSHRLMNAMEN1KMT2ACA12
SCHEMBL13297947 0.75 CES2 (0.44) TSHRALDH1A1MEN1KMT2A
SCHEMBL50039 0.74 TSHR (1.00) TSHRGLALMNAALDH1A1MEN1
SCHEMBL28238018 0.74 TSHR (1.00) TSHRGLALMNAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4634184-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY Crossfire Oncology Holding B.V. (NL) 2025-10-22 EP disclosed
US-20250288549-A1 SYNTHETIC PROCESS FOR PRODUCTION OF LIPOXIN B4 AND ANALOGUES THEREOF UNIVERSITY HEALTH NETWORK (CA) 2025-09-18 US disclosed
US-20250074911-A1 MACROCYCLIC BTK INHIBITORS CROSSFIRE ONCOLOGY HOLDING B.V. (NL) 2025-03-06 US disclosed
EP-4448523-A1 MACROCYCLIC BTK INHIBITORS Crossfire Oncology Holding B.V. (NL) 2024-10-23 EP disclosed
EP-4448521-A1 REVERSIBLE MACROCYCLIC KINASE INHIBITORS Crossfire Oncology Holding B.V. (NL) 2024-10-23 EP disclosed
CN-118696041-A Macrocyclic BTK inhibitors 克罗斯费尔肿瘤学控股有限公司 2024-09-24 CN disclosed
WO-2024126617-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY CROSSFIRE ONCOLOGY HOLDING B.V. (NL) 2024-06-20 WO disclosed
WO-2023205908-A1 SYNTHETIC PROCESS FOR PRODUCTION OF LIPOXIN B4 AND ANALOGUES THEREOF UNIVERSITY HEALTH NETWORK (CA) 2023-11-02 WO disclosed
WO-2023110936-A1 REVERSIBLE MACROCYCLIC KINASE INHIBITORS NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) 2023-06-22 WO disclosed
WO-2023110970-A1 MACROCYCLIC BTK INHIBITORS NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) 2023-06-22 WO disclosed
US-20090291916-A1 Trihydroxy Polyunsaturated Eicosanoid UNIVERSITY OF SOUTHERN CALIFORNIA 2009-11-26 US disclosed
US-20090291916-A1 Trihydroxy Polyunsaturated Eicosanoid UNIVERSITY OF SOUTHERN CALIFORNIA 2009-11-26 US disclosed
US-7582785-B2 Trihydroxy polyunsaturated eicosanoid derivatives UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-09-01 US disclosed
US-7582785-B2 Trihydroxy polyunsaturated eicosanoid derivatives UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-09-01 US disclosed
WO-2008118457-A2 SYNTHESIS OF RESOLVINS AND INTERMEDIATES, COMPOUNDS PREPARED THEREBY, AND USES THEREOF UNIVERSITY OF MEDICINE AND DENTISTRY OF NJ (US) 2008-10-02 WO disclosed
EP-0866791-B1 DIAMINOPYRIMIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIBACTERIAL ARPIDA AG (CH) 2002-01-30 EP disclosed
EP-1149834-A1 Diaminopyrimidines, pharmaceutical compositions containing them and their use as antibacterial F. HOFFMANN-LA ROCHE AG (CH) 2001-10-31 EP disclosed
EP-0866791-A1 DIAMINOPYRIMIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIBACTERIAL F. HOFFMANN-LA ROCHE AG (CH) 1998-09-30 EP disclosed
US-5773446-A BACTERICIDES; CONTROLLING INFECTIONS HOFFMANN-LA ROCHE INC. (US) 1998-06-30 US disclosed
WO-1997020839-A1 DIAMINOPYRIMIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIBACTERIAL F. HOFFMANN-LA ROCHE AG (CH) 1997-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291916-A1 Trihydroxy Polyunsaturated Eicosanoid ALOX5, ALOX15, ALOX15B TSHR 1124/4885GLA 3604/4885LMNA 2150/4885
US-20250288549-A1 SYNTHETIC PROCESS FOR PRODUCTION OF LIPOXIN B4 AND ANALOGUES THEREOF LTB4R, LTB4R2, ALOX15B TSHR 1182/4885GLA 839/4885LMNA 1557/4885
US-20250074911-A1 MACROCYCLIC BTK INHIBITORS BTK, LYN, LCK TSHR 2394/4885GLA 3395/4885LMNA 3689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.